Revelation Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Revelation Biosciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-287.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-287.4%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections

Mar 28

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: REVB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: REVB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Revelation Biosciences Piyasaya Karşı Temettü Getirisi

REVB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (REVB)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (REVB) (3 yıla kadar)	n/a

Önemli Temettü: REVB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, REVB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: REVB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: REVB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Revelation Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Financial position

Revelation Biosciences Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

New major risk - Share price stability

Revelation Biosciences Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Revelation Biosciences, Inc. Has Completed Dosing of Its First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc., Annual General Meeting, May 15, 2024

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.183326 million.

Investor sentiment deteriorates as stock falls 19%

New major risk - Share price stability

Revelation Biosciences Announces Reverse Stock Split to Regain Compliance

Revelation Biosciences, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla to Board of Directors

Price target decreased by 93% to US$11.45

Revelation Biosciences Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for its Common Stock

Revelation Biosciences, Inc. announced delayed 10-Q filing

Revelation Biosciences, Inc., Annual General Meeting, Jun 09, 2023

Independent Chairman recently bought US$60k worth of stock

Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300

High number of new and inexperienced directors

Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

Price target decreased to US$5.00

Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease

Revelation Biosciences surges 46% on licensing deal with Vanderbilt University

Revelation Biosciences GAAP EPS of -$0.12

Revelation Biosciences stock slides 47% on pricing $5M securities offering

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Revelation Biosciences, Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Price target decreased to US$9.00

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Revelation Biosciences Receives Non-Compliance Letter from Nasdaq

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

Revelation Biosciences, Inc. announced delayed annual 10-K filing

Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections

Chairman recently bought US$133k worth of stock

Chairman recently bought US$128k worth of stock

Revelation Biosciences, Inc. announced that it expects to receive $7.598001 million in funding

Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2B Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection

Revelation Biosciences Inc. Announces Enroll and Dose First Patient in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis

No independent directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin